Renal denervation in the treatment of resistant arterial hypertension.
Patients with resistant arterial hypertension have an increased risk of stroke, myocardial infarction, heart failure, and chronic kidney disease. In many cases, limitations of pharmacological treatment like intolerance and adherence to the antihypertensive medications are present in the clinical setting. In this context, new treatment options like trans-femoral sympathetic renal nerve denervation is, even after publication of the Symplicity HTN-3 trial, a promising new treatment option.
1st Medical Department of Cardiology, Linz General Hospital, Johannes Kepler University School of Medicine, Krankenhausstraße 9, 4020, Linz, Austria, thomas.lambert@akh.linz.at.
Thomas
T
Lambert
Wilhelm
W
Schützenberger
Clemens
C
Steinwender
D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000502:physiology; D004351:Drug Resistance; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000503:physiopathology / Q000628:therapy*; D007668:Kidney / Q000294:innervation*; D013562:Sympathectomy / Q000379:methods*; D013564:Sympathetic Nervous System / Q000503:physiopathology
D000959:Antihypertensive Agents